



# 25<sup>th</sup> Annual Cancer Progress Conference

## March 4 - 5, 2014

### New York

## AGENDA

Tuesday, March 4, 2014

- 7:00 - 8:00am**                      **Registration and Continental Breakfast**
- 8:00 - 8:15am**                      **Opening Remarks**
- Jeff Bockman, PhD, VP, Defined Health
- 8:15 - 8:45am**                      **Keynote Address**
- Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline
- 8:45 - 10:00am**                    **Taking Immunotherapy Seriously: New Targets and Combinations**
- Moderator:
- Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline
- Panelists:
- Jeff Bockman, PhD, VP, Defined Health
  - Ira Mellman, PhD, VP, Research Oncology, Genentech
  - Galit Rotman, PhD, Chief Scientist of Therapeutics, Compugen
  - Michel Sadelain, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
  - Lauren V. Wood, MD, Senior Clinical Investigator, Vaccine Branch, National Cancer Institute
- 10:00 - 10:30am**                    **Networking Break**
- 10:30 - 11:45am**                    **Brain Cancer - Tackling the Intractable: Novel Targets and Approaches**
- Moderator:
- Minesh P. Mehta, MD, Medical Director, Maryland Proton Treatment Center, University of Maryland
- Panelists:



- Lauren Abrey, MD, Oncology Development Site Head, F. Hoffmann-La Roche Inc.
- Thomas Davis, MD, CMO and SVP Clinical Development, Celldex Therapeutics
- H. Ian Robins, MD, PhD, Faculty, University of Wisconsin School of Medicine and Public Health
- Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics

11:45 - 1:00pm

**Big Data and Cancer:  
Transforming Patient Care by Turning Data into Decisions**

Moderator:

- Colin Hill, Chief Executive Officer, President & Chairman, GNS Healthcare

Panelists:

- Alexis Borisy, Entrepreneur in Residence, Third Rock Ventures
- Joel Dudley, PhD, Director of Biomedical Informatics and Assistant Professor of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai
- Brian Leyland-Jones, MD, VP, Molecular and Experimental Medicine, Avera Health
- Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna
- Timothy J. Thompson, CEO, Intervention Insights

1:00 - 2:15pm

**Networking Luncheon**

2:15 - 3:30pm

**Evidentiary Standards for Diagnostics: When does a Biomarker Become a Diagnostic for Cancer Treatment?**

Moderator:

- Steven Averbuch, MD, VP, Translational Clinical Development & Pharmacodiagnosics, Bristol-Myers Squibb Company

Panelists:

- Anna Barker, PhD, Director, Transformative Healthcare Networks, Arizona State University
- Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
- Steven Gutman, MD, Strategic Advisor, Myraqa
- Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna



- Howard I. Scher, MD, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center
- Kim Zerba, PhD, Group Director, Global Biometric Sciences, Bristol-Myers Squibb

**3:30 - 4:00pm**

**Networking Break**

**4:00 - 5:15pm**

**Oncology R&D: ROI and the New Expectations**

Moderator:

- Steve Heller, Principal, OncStrat LLC

Panelists:

- Walter Capone, President, The Multiple Myeloma Research Foundation
- Jeanne Farrell, PhD, Business Development Director, Icahn School of Medicine at Mount Sinai
- Debasish Roychowdhury, MD, President, Nirvan Consultants, LLC
- Mark J. Simon, Advisor, Torreya Partners LLC

**5:15 - 6:30pm**

**New Treatment Options for Prostate Cancer**

Moderator:

- Jeremy P. Goldberg, President, JPG Healthcare LLC

Panelists:

- Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
- Marco Gottardis, Ph D, VP and Prostate Cancer Disease Area Stronghold Leader, Oncology Therapeutic Area, Janssen Research & Development, LLC
- Richard Heyman, CEO, Seragon (ex-CEO Aragon)
- Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
- Marianne Sadar, PhD, Distinguished Scientist, BC Cancer Agency. Professor of Pathology and Laboratory Medicine, University of British Columbia

**6:30 - 8:30pm**

**Cancer Progress 2014 Reception**

---



**Wednesday, March 5, 2014**

**7:00 - 8:00am Continental Breakfast**

**8:00 - 8:15am Opening Remarks**

- Mike Rice, MS, MBA, Senior Consultant, Defined Health

**8:15 - 9:15am Keynote Address - A Trialogue: Valuing Value in Oncology**

Moderator:

- Ed Saltzman, President, Defined Health

Panelists:

- Peter Bach, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center
- Professor David Haslam, CBE, FRCGP, FRCP, FFPH Chairman, NICE
- Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 2013-2014 President, ASCO

**9:15 - 10:30am Antibody-Drug Conjugates:  
Supercharging the Blockbuster Antibody Class**

Moderator:

- Jeff Bockman, PhD, VP, Defined Health

Panelists:

- Robert Cohen, MD, Calico Life Sciences
- Jonathan Drachman, MD, SVP, Research and Translational Medicine, Seattle Genetics
- Hans-Peter Gerber, PhD, VP, BioConjugate Discovery & Development, Oncology Research, Pfizer
- John Lambert, PhD, EVP, Research & Development & Chief Scientific Officer, ImmunoGen, Inc.
- Peter Kiener, Ph D, Chief Scientific Officer, Ambrx, Inc.

**10:30 - 10:45am Networking Break**

**10:45 - 12:00pm Cancer Gene & Cell Therapy:  
Expanding Therapeutic Options With Living Drugs**

Moderator:



- Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

- Estuardo Aguilar-Cordova, PhD, Chief Executive Officer Advantagene, Inc.
- Renier J. Brentjens, MD, PhD, Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center
- Nori Kasahara, M.D., Ph.D., Director, CURE Vector Core Facility JCCC Vector Shared Resources, Professor, Department of Medicine, Molecular & Medical Pharmacology, UCLA
- Angela Shen, MD, MBA, Global Clinical Program Head, CTL019, Oncology Clinical Development, Novartis Pharmaceuticals Corp

**12:00 - 1:15pm**

**Intrinsic and Acquired Resistance in Cancer:  
Getting Smarter About Combinations and Sequencing**

Moderator:

- Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center

Panelists:

- Jeffrey A. Engelman, MD, PhD, Director of Thoracic Oncology and Director of Molecular Therapeutics, Massachusetts General Hospital Cancer Center
- Greg Plowman, MD, PhD, VP, Oncology Research Eli Lilly and Company
- David Solit, MD, Director, Developmental Therapeutics, Memorial Sloan Kettering Cancer Center

**1:15 - 2:30pm**

**Networking Luncheon**

**2:30 - 3:45pm**

**Challenging Established Paradigms in Cancer**

Moderator:

- Sol J. Barer, PhD, SJBarer Consulting LLC

Panelists:

- Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation
- Giulio Draetta, MD, PhD, Director, Institute for Applied Cancer Science, Professor, Genomic Medicine, MD Anderson Cancer Center
- Tak Mak, PhD, University Professor, Ontario Cancer Institute, University of Toronto



- Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center

**3:45 - 4:00pm**

**Networking Break**

**4:00 - 5:15pm**

**Translational Oncology: How to Better Transform Targets into Relevant Drugs for Patients**

Moderators:

- Jeffrey M. Bockman, PhD, VP, Defined Health
- Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

- Joseph Beechem, PhD, SVP, Research and Development, NanoString Technologies
- Pamela Carroll, PhD, VP, Oncology, Innovation Center in Boston, Janssen Research & Development
- Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation
- Victoria Richon, PhD, VP and Head of Cancer Research, Discovery and Early Development, Sanofi
- Spiro G. Rombotis, President & CEO, Cyclacel Pharmaceuticals, Inc.

**5:15pm**

**Closing Remarks**

**5:30pm**

**Cancer Progress 2014 Conference Concludes**